Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin 18.2 (CLDN18.2; A2 isoform of claudin-18) conjugated to an as of yet undisclosed cytotoxic payload, with potential antineoplastic activity. Upon administration, anti-CLDN18.2 ADC AZD4360 specifically targets and binds to CLDN18.2 expressed on tumor cells. Upon internalization and release, the cytotoxic payload will induce, through an as of yet unelucidated mechanism of action, apoptosis in CLDN18.2-expressing tumor cells. In addition, AZD4360 causes a bystander effect, thereby also killing neighboring CLDN18.2-negative tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.

**Synonyms:** - AZD 4360 - AZD-4360 - AZD4360 - Anti-CLDN18.2 ADC AZD4360 - Anti-Claudin 18.2 ADC AZD4360